Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

The Journal of infectious diseases - 1 Dec 2005

Gallant Joel E, Rodriguez Allan E, Weinberg Winkler G, Young Benjamin, Berger Daniel S, Lim Michael L, Liao Qiming, Ross Lisa, Johnson Judy, Shaefer Mark S

Abstract excerpt

BACKGROUND: Antiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy. We compared 2 regimens dosed as 2 pills once daily. METHODS: This was a randomized, open-label, multicenter study of tenofovir disoproxil fumarate versus efavirenz, both administered once daily with the abacavir/lamivudine fixed-dose combination in treatment-naive human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Lamivudine

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Share to Tenofovir

Share to Treatment Failure

Source

Identifiers

PMID: 16267763
DOI: 10.1086/498069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.PMID 16267763Read ↗

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.Semantic proximity Read ↗

Early virological failure with a combination of tenofovir, didanosine and efavirenz.Semantic proximity Read ↗

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.Semantic proximity Read ↗

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Semantic proximity Read ↗

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.Semantic proximity Read ↗

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.Semantic proximity Read ↗

Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.Semantic proximity Read ↗

Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistanceSemantic proximity Read ↗

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.Semantic proximity Read ↗

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.